3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
28
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumours
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Metastatic Castration Resistant Prostate Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Small Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
enzalutamide
6
Abiraterone Acetate
4
niraparib
2
Prednisone
2
xentuzumab
1
tasquinimod
1
pembrolizumab
1
darolutamide
1
atezolizumab
1
abiraterone
1
Nivolumab
1
Drug Therapy
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Prostatic Neoplasms, Castration-Resistant
×
abiraterone
×
Clear all
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts